+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07887971

Evaluation of Intravenous 225AcAc-AKY-2519 for B7-H3 Positive Solid Tumors in a Phase 1b Multicenter Study

Led by Aktis Oncology, Inc. · Updated on 2026-11-02

152

Participants Needed

2

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the safety, tolerability, and behavior of two radiopharmaceutical drugs, 64CuCu-AKY-2519 and 225AcAc-AKY-2519, in adults with B7-H3 positive solid tumors. This Phase 1b study includes patients with advanced or metastatic tumors such as non-small cell lung cancer, small cell lung cancer, metastatic prostate cancer, head and neck cancer, esophageal cancer, and colorectal cancer. The trial is conducted in two parts dose escalation and dose expansion to evaluate preliminary anti-tumor effects and safety. The study involves two phases Part 1 tests increasing doses of 225AcAc-AKY-2519 to find safe levels and includes a backfill strategy to further evaluate two dose levels. Part 2 expands dosing to two cohorts, one with non-small cell lung cancer and another with other solid tumors, to assess the treatments effects. Both drugs are given intravenously, with 64CuCu-AKY-2519 used for imaging and 225AcAc-AKY-2519 for therapy. Participants will undergo multiple assessments including imaging scans to confirm tumor size, laboratory tests to check organ function, and monitoring for adverse effects during and after treatment. Researchers will track serious adverse events, dose-limiting toxicities, objective tumor responses, duration of response, and progression-free survival for up to five years. The study involves regular visits for drug administration and follow-up evaluations to measure treatment impact and safety.

CONDITIONS

Brief Title

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

Research Team

T

TIffany Wang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here